| 1.6 0.12 (8.11%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.52 | 1-year : | 3.22 |
| Resists | First : | 2.16 | Second : | 2.76 |
| Pivot price | 1.72  |
|||
| Supports | First : | 1.2 | Second : | 0.99 |
| MAs | MA(5) : | 1.5 |
MA(20) : | 1.81 |
| MA(100) : | 2.08 |
MA(250) : | 1.6 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 34.4 |
D(3) : | 30.9 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 3.96 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RFL ] has closed above bottom band by 38.4%. Bollinger Bands are 17% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.62 - 1.63 | 1.63 - 1.63 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.59 - 1.6 | 1.6 - 1.61 |
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Thu, 08 Oct 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL - PR Newswire
Sun, 04 Oct 2026
Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing - TradingView
Thu, 01 Oct 2026
We're Keeping An Eye On Rafael Holdings' (NYSE:RFL) Cash Burn Rate - Simply Wall Street
Wed, 30 Sep 2026
Why Is Rafael Stock Falling Wednesday? - Benzinga
Wed, 30 Sep 2026
Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint - Yahoo Finance
Wed, 30 Sep 2026
The trial drug missed its main goal. Separately, treatment was associated with 85% lower mortality risk. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.177e+007 (%) |
| Held by Institutions | 38.2 (%) |
| Shares Short | 400 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.624e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 837.9 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 980000 % |
| Gross Profit (p.s.) | -126.5 |
| Sales Per Share | -94 |
| EBITDA (p.s.) | 2.33e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.44 |
| Dividend | 0 |
| Forward Dividend | 791280 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|